Advertisement

Picture Swiss Biotech Association LSE Global Village 2025 Basel 650x100px
Organisation › Details

Ethris GmbH

Ethris has paved a new path from genes to therapeutic proteins using its proprietary, non-immunogenic messenger RNA technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, we are a global leader in delivering stabilized mRNAs directly to the respiratory system via optimized formulation and nebulization technologies. We are rapidly advancing our pipeline of immuno-modulation and mRNA-based protein replacement therapies with the ultimate goal of improving patients’ lives. *

 

Period Start 2009-12-31 established
Products Industry SNIM®RNA technology
  Industry 2 ETH47 (Ethris)
Persons Person Rudolph, Carsten (Ethris 201301 Managing Director + Co-Founder)
  Person 2 Planck, Christian (Ethris 201301 Managing Director + Co-founder)
     
Region Region Martinsried
  Country Germany
  Street 3 Semmelweisstr.
  City 82152 Planegg
  Tel +49-89-8955788-0
    Address record changed: 2024-01-05
     
Basic data Employees B: 11 to 50 (2013-01-07)
     
    * Document for »About Section«: Ethris GmbH. (2/1/22). "Press Release: Ethris Raises $26.3 Million Series B to Advance Pipeline of mRNA-based Therapeutics for Respiratory Diseases". Munich.
     
   
Record changed: 2024-12-29

Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

More documents for Ethris GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association LSE Global Village 2025 Basel 650x300px




» top